Kurt Zatloukal
CEO

Kurt Zatloukal is co-founder and CEO of Medcount Technologies GmbH. He was Professor of Pathology and head of Diagnostics and Research Center for Molecular Biomedicine at the Medical University of Graz, Austria. Fields of expertise range from basic research in molecular pathology of metabolic diseases and cancer to biobanking and quality management which includes the contribution to several ISO Standards related to in vitro diagnostic devices, research on high risk pathogens and drug development.

David Gabriel
CEO

David Gabriel is co-founder and CEO of Medcount Technologies GmbH. As a medical doctor and former anesthesiologist, he brings 25 years of entrepreneurial experience in developing and leading medical projects. He is also founder and CEO of CBRN.ZONE and the European Emergency Academy. His fields of expertise include CBRN safety solutions, medical biodefense, emergency training and strategy development for CBRN preparedness and medical countermeasures. As an investor, he focuses on innovative solutions in healthcare, CBRN safety, medical preparedness and training.

Bernhard Zatloukal
CIO and Cybersecurity

Bernhard Zatloukal is co-founder and CIO of Medcount Technologies GmbH. He is Senior Software Developer at fragmentiX Storage Solutions GmbH. His fields of expertise are secure data storage solutions, implementation of cryptographic algorithms and IT security in general. He was involved in the design and implementation of several studies concerning the secure handling of sensitive medical, research, and government data, both at rest and in transit, with a focus on cryptographic data protection, protocol design, and system-level resilience – including architectures employing information-theoretic security and post-quantum cryptography. He studied Mathematics at the Technical University of Graz.

Johannes Zatloukal
AI & Knowledge Management

Johannes Zatloukal is co-founder of Medcount Technologies GmbH. He studied medicine at the University of Pécs Medical School in Hungary and eHealth at the University of Applied Sciences Joanneum in Graz, Austria. He was part of a dermatological research team at the Medical University of Graz and is currently a student employee at Siemens Austria. He is experienced with team coordination and project management in cooperation with international companies. Due to his activities at the Institute of Dermatology and Venerology in Graz and his work at Siemens Austria he is conversant with data analyses and AI development in a medical context.

Razvan Neagu
Research, Regulatory & EU Innovation Strategy  

Razvan Neagu is a PhD pharmacist and innovation professional at Medcount Technologies GmbH with strong expertise in EU-funded research, regulatory strategy, and health security innovation. He brings extensive experience in European Defence projects, supporting the development and positioning of advanced medical countermeasures within EU regulatory and policy frameworks. His work focuses on translating scientific innovation into fundable, compliant, and market-relevant solutions through strategic partnerships with industry, research organisations, and European institutions.

Christina Weisser
Scientist

Christina Weisser is a researcher at Medcount Technologies GmbH, focusing on plant growth and transformation optimization. She has a Master’s degree in Biology from the Karl-Franzens-University in Graz were she focused on the analysis of protein and gene expression in agroinfiltrated plants like Arabidopsis thaliana and Nicotiana benthamiana as well as in invertebrates such as ants.

Markus Sack
Plant Molecular Farming Advisor

Markus Sack started his work in Plant Molecular Farming in 1995 and pioneered the rapid and scalable Agrobacterium-mediated transient gene expression. He was involved in progressing a tobacco-derived HIV antibody 2G12 into clinical phase I trials and in several projects for producing HIV and Rabies antibodies, and novel Malaria vaccine candidates by various Plant Molecular Farming systems. He is experienced in human antibody repertoires, continuous fermentation of plant suspension cells, the “plant-cell pack” technology and SPR analysis. For more than 20 years he has been involved in setting up Agro-infiltration R&D laboratories across the world and increasing scale and throughput to support product screening and development and purification of plant-derived proteins. Since August 2019 he is CEO of Pro-SPR GmbH, a start-up consulting for SPR assay development and validation and Plant Molecular Farming in general.

Péter Gebhardt
EU Strategic Advisor

Péter Gebhardt studied at the University of Pécs and at Semmelweis University and completed his internship at the Csolnoky Ferenc Hospital in Veszprém. He worked as a research assistant in Berlin and Barcelona before starting his business career as a financial data analyst at PRK Global in the pharmaceutical and biotechnology fields. Later, he transferred to the Bioderma Hungary where he worked as a medical representative and a salesperson. He became the head of cardiology at BTL Hungary. He has been working at the Hungarian Development Promotion Office since 2023 from Brussels. He has significant experience in the fields of R&D, institutional communication, EU-funded projects, healthcare IT systems, procurement and international networking.